The triplet gemcitabine (G), epirubicin (E) and docetaxel (Doc) is feasible, safe and highly active as primary systemic therapy (PST) of patients (pts) with multicentric phase I/II trial

Authors :: G. Bastert
R. Hamerla
J Huober
Uwe Wagner
D. von Fournier
Andreas Schneeweiss
K. Krauss
D. Wallweiner
F. Beldermann
Matthias Geberth
Source :: The Breast. 12:S36
Publication Year :: 2003
Publisher :: Elsevier BV, 2003.

Subjects :: Oncology
medicine.medical_specialty
business.industry
General Medicine
Systemic therapy
Gemcitabine
Surgery
Phase i ii
Docetaxel
Internal medicine
medicine
business
medicine.drug
Epirubicin

Tools